Emerging evidence suggests GLP-1 drugs may reduce overall cancer risk, though questions remain about specific cancer types
The explosive popularity of GLP-1 weight-loss medications like Wegovy, Ozempic, and Zepbound has prompted urgent questions about their long-term health effects—particularly their relationship with cancer. As millions of Americans turn to these drugs for weight management, scientists are racing to understand their cancer implications.
The answer is more nuanced than many expected, with encouraging findings alongside some areas requiring continued vigilance.
>>>Check out What Are GLP-3 Drugs? The New Triple-Action Weight-Loss Medications Explained<<<
The Obesity-Cancer Connection
Understanding how weight-loss drugs affect cancer risk requires first recognizing obesity’s role as a cancer driver. Obesity has been identified in at least 13 forms of cancer, including breast, endometrial, colon, gastric, prostate and more.
Given this established link, the hypothesis that medications helping people lose substantial weight might reduce cancer risk seems logical. Recent research is beginning to confirm this theory—with important caveats.
>>>Check out Weight-Loss Drugs Like Ozempic Linked to Mental Health Risks<<<
Major Study Shows Overall Cancer Risk Reduction
A landmark study published in JAMA Oncology in August 2025 provided compelling evidence. The study included 86,632 matched adults and found that the incidence rates of 14 cancers were 13.6 vs 16.4 per 1000 person-years, indicating a significantly lower overall cancer risk among individuals taking GLP-1RAs compared with nonusers.
This translates to approximately a 17% reduction in new cancer diagnoses when compared with similar adults who didn’t take these medications.
The research revealed reduced risk for certain cancer types. Taking GLP-1RAs was associated with a reduced risk of endometrial cancer, ovarian cancer, and meningioma.
Additional research found colorectal cancer benefits. A large study in JAMA Oncology found GLP-1 receptor agonists did reduce the risk of colorectal cancer, with the drug being especially helpful in reducing colon cancer risk in those who were obese and overweight.
Conflicting Research Findings
However, a December 2025 study in Annals of Internal Medicine reached different conclusions. Despite previous excitement around a potential link between GLP-1 drugs and a reduced risk of cancer, new research suggests the popular medications probably have little or no effect on a person’s risk of developing one of the 13 obesity-related cancers.
Researchers acknowledge these medications haven’t been in widespread use long enough to detect cancer prevention effects fully. If you were to look at people who smoked for one year, you may not see a big impact of tobacco use. You need to follow them up for a longer time to really see the effects of tobacco on cancer development, explained Dr. Michael McGuire from VCU Health.
The Thyroid Cancer Question
The most discussed concern involves thyroid malignancies, stemming from animal studies where large amounts of these drugs were given, and the animal model would get what’s called C cell hyperplasia, which is a precursor to medullary thyroid cancer.
However, recent human studies provide reassurance. In a large multisite study utilizing data from six population-based databases, researchers found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer with follow-up ranging from 1.8-3.0 years.
>>>Read Why GLP-1 Weight-Loss Drugs Can Cause Hair Loss<<<
What This Means for Patients
For most people considering these medications, emerging cancer data appears reassuring. Overall cancer risk appears lower among users, with particular benefits for obesity-related malignancies.
Nobody comes to me and says, ‘I’d like to go on some medication to reduce my cancer risk. They’re going on these medications to lose weight, to improve their diabetes, their sleep apnea, their heart failure—all their obesity-related conditions, but not cancer, notes Dr. Susan Wolver from VCU Health.
Any cancer prevention benefits should be viewed as potential added bonuses to the drugs’ primary purposes—not reasons to start them without other indications.
>>>See also Unlocking Brain Health: The Role of the MIND Diet<<<
The Bottom Line
The relationship between GLP-1 weight-loss drugs and cancer remains an evolving story. Current evidence suggests overall cancer risk decreases among users, likely due to weight loss and metabolic improvements.
As these medications have only been in widespread use for a few years, definitive long-term cancer data won’t emerge for another decade. For now, cancer considerations shouldn’t be the primary factor in medication decisions—but accumulating evidence provides reassurance they’re unlikely to increase overall cancer risk and may offer protective benefits for several cancer types.